Impact of ECOG performance status 2 participants on outcomes of pivotal cancer clinical trials: a meta-analysis and meta-regression
Although PS 2 participants showed a greater propensity to serious toxicity, no significant differences in efficacy outcomes were observed compared with those with PS ≤1. Our results support the inclusion of PS 2 participants in clinical trials, as their exclusion limits the generalizability of results.
Authors
- J. Gulley
- D. Giannarelli
- G.M. Iannantuono
- A. Vitale
- P. Navarra
- T. Giovagnoli
- B. Gyawali
- S. Sganga
- F. Lo Bianco
- G. Daniele
- L. Mastrantoni
- M. Filetti
- E. Giudice
- E. Bria
- A. Spinazzola
- C.S. Floudas
Institutions
- Università Cattolica del Sacro Cuore (IT)
- National Institutes of Health (US)
- Humanitas University (IT)
- Queen's University (CA)
- Agostino Gemelli University Polyclinic (IT)
- National Cancer Institute (US)
- Center for Cancer Research (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106065
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00